Dengue fever

J&J drops phase 2 dengue candidate in latest shift from vaccines

Johnson & Johnson’s deprioritization of its infectious disease pipeline has claimed another victim in the form of its dengue virus vaccine mosnodenvir

James Waldron Oct 4, 2024 10:14am

J&J links antiviral to protection from dengue in challenge trial

Oct 20, 2023 9:30am

Atea dumps dengue drug as forecast R&D timelines, costs spiral

Mar 1, 2023 6:50am

Novartis, GSK commit $1.25B to tropical disease R&D

Jun 23, 2022 5:52am

Takeda's data ready first dengue travel shot for approval

Jun 9, 2022 4:30am

T-cell adaptive vaccines close in on data in dengue, COVID-19

Apr 18, 2022 8:30am